Ring-substituted quinolines as potential anti-tuberculosis agents. 2004

Suryanarayana Vangapandu, and Meenakshi Jain, and Rahul Jain, and Sukhraj Kaur, and Prati Pal Singh
Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Sector 67, S.A.S. Nagar, Punjab 160 062, India.

We report in vitro antimycobacterial properties of ring-substituted quinolines (series 1-4) constituting 56 analogues against drug-sensitive and drug-resistant M. tuberculosis H37Rv strains. The most effective compounds 2h (R1 = R2 = c-C6H11, R3 = NO2, series 1) and 13g (R1 = OC7H15, R2 = NO2, series 4) have exhibited an MIC value of 1 microg/mL against drug-sensitive M. tuberculosis H37Rv strain that is comparable to first line anti-tuberculosis drug, isoniazid. Selected analogues (2d, 2g, 2h, 4e, 6b, 13b, 13g, and 14e, MIC: < or = 6.25 microg/mL) upon further evaluation against single-drug-resistant (SDR) strains of M. tuberculosis H37Rv have produced potent efficacy in the range between 6.25 and 50 microg/mL.

UI MeSH Term Description Entries
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D011804 Quinolines
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D014376 Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS. Koch's Disease,Kochs Disease,Mycobacterium tuberculosis Infection,Infection, Mycobacterium tuberculosis,Infections, Mycobacterium tuberculosis,Koch Disease,Mycobacterium tuberculosis Infections,Tuberculoses
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D018088 Tuberculosis, Multidrug-Resistant Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS. Tuberculosis, Drug-Resistant,Tuberculosis, MDR,Tuberculosis, Multi-Drug Resistant,Drug-Resistant Tuberculosis,MDR Tuberculosis,Multi-Drug Resistant Tuberculosis,Multidrug-Resistant Tuberculosis,Tuberculosis, Drug Resistant,Tuberculosis, Multi Drug Resistant,Tuberculosis, Multidrug Resistant

Related Publications

Suryanarayana Vangapandu, and Meenakshi Jain, and Rahul Jain, and Sukhraj Kaur, and Prati Pal Singh
March 2023, Archiv der Pharmazie,
Suryanarayana Vangapandu, and Meenakshi Jain, and Rahul Jain, and Sukhraj Kaur, and Prati Pal Singh
September 2004, European journal of medicinal chemistry,
Suryanarayana Vangapandu, and Meenakshi Jain, and Rahul Jain, and Sukhraj Kaur, and Prati Pal Singh
January 2020, Current topics in medicinal chemistry,
Suryanarayana Vangapandu, and Meenakshi Jain, and Rahul Jain, and Sukhraj Kaur, and Prati Pal Singh
November 2013, European journal of medicinal chemistry,
Suryanarayana Vangapandu, and Meenakshi Jain, and Rahul Jain, and Sukhraj Kaur, and Prati Pal Singh
September 1983, Archiv der Pharmazie,
Suryanarayana Vangapandu, and Meenakshi Jain, and Rahul Jain, and Sukhraj Kaur, and Prati Pal Singh
February 2006, Bioorganic & medicinal chemistry,
Suryanarayana Vangapandu, and Meenakshi Jain, and Rahul Jain, and Sukhraj Kaur, and Prati Pal Singh
January 1990, Life sciences,
Suryanarayana Vangapandu, and Meenakshi Jain, and Rahul Jain, and Sukhraj Kaur, and Prati Pal Singh
June 2019, Steroids,
Suryanarayana Vangapandu, and Meenakshi Jain, and Rahul Jain, and Sukhraj Kaur, and Prati Pal Singh
August 2015, Bioorganic & medicinal chemistry,
Suryanarayana Vangapandu, and Meenakshi Jain, and Rahul Jain, and Sukhraj Kaur, and Prati Pal Singh
October 2015, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!